23 Feb Avectas
Michael Maguire, Ph.D., CEO
Avectas is a cell engineering company that has pioneered – SOLUPORE® – a proprietary simple, highly effective automated transfection system to enable efficient and safe genetic modification, for the next generation of immuno-oncology therapies. Combined with technical and regulatory support, the company is partnering with cell therapy companies to address emerging cell delivery challenges associated with multiple cell modifications and engineering of cells that are limited or fragile. SOLUPORE® has strong intellectual property protection through granted and pending patents, including in the US and Europe. Avectas is a private, international company with research facilities in Dublin, Ireland and Toronto, Canada as well as an office in Cambridge MA, USA. It has almost 40 employees and is led by a team of highly experienced pharmaceutical executives, who are supported by a world class Scientific Advisory Board of cancer cell therapy experts. The Company has raised over US$40m to date.